Infarct size reduction in patients with STEMI: why we can do it!

Area of Science:

• Cardiology
• Cardiovascular Research
• Translational Medicine

Background:

• Significant advancements in ST-elevation myocardial infarction (STEMI) treatment over 30 years.
• Reducing infarct size is crucial for patient prognosis in STEMI.
• Current treatments prioritize rapid reperfusion and preventing reocclusion of the coronary artery.

Purpose of the Study:

• To highlight the importance of reducing infarct size in STEMI patients.
• To underscore the existence and significance of lethal reperfusion injury.
• To advocate for protective interventions against reperfusion injury alongside reperfusion therapy.

Main Methods:

• Review of preclinical research characterizing animal models of acute myocardial infarction (MI).
• Analysis of major determinants of infarct size: area at risk, collateral flow, ischemia duration, and reperfusion timing.
• Evaluation of recent clinical trial data and proof-of-concept studies in STEMI patients.

Main Results:

• Lethal reperfusion injury is a significant factor in STEMI outcomes and can be prevented.
• Infarct size reduction is achievable in STEMI patients by considering key determinants.
• Phase II clinical trials show encouraging results for infarct size reduction strategies.

Conclusions:

• Future STEMI treatment should integrate strategies to mitigate lethal reperfusion injury.
• Translating knowledge from animal models to clinical practice is key for improving STEMI management.
• Improved study designs incorporating determinants of infarct size will advance therapeutic development for STEMI.